ArticleJournal of neurology2026
DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo gather expert consensus regarding initiation of monoclonal high-efficacy therapies (HET) amongst treatment-naïve relapsing-remitting multiple sclerosis (RRMS) patients in France.
methodsThe study leveraged the Delphi method to gauge consensus amongst an expert panel of 31 neurologists. Eight clinical cases with demographic, clinical and imaging characteristics were presented, prompting the experts to respond if they would recommend monoclonal HET. Additionally, potentially influential parameters were changed one at a time to assess whether the experts would recommend monoclonal HET. After a first round, an e-workshop was conducted to discuss non-consensual statements, which were re-submitted for rating (Round 2). Characteristics influencing monoclonal HET initiation were evaluated.
results31/31 experts responded to both rounds. Consensus for or against monoclonal HET was reached for 89/108 (82.4%) statements. Factors that systematically led to monoclonal HET initiation were high brain lesion load (>20 lesions), ≥2 spinal cord lesions, ≥3 gadolinium-enhancing lesions and ≥3 infratentorial lesions. A single spinal cord lesion, in combination with other factors (which, in isolation, often but not always led to monoclonal HET), systematically led to monoclonal HET recommendation.
conclusionThis study suggests that the panel of French neurologists favoured monoclonal HET initiation amongst treatment-naïve RRMS patients with high radiological disease activity, whereas clinical characteristics played a complementary role.
Indexed as
Identifiers
42911241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.